Amarin Fights Flames Of Investor Unrest
Confident Of European Growth For Vazkepa
Derided by largest shareholder Sarissa as ‘dawdling’ and ‘lackadaisical,’ the board at Amarin has come out fighting, saying that a strategy of growing its heart drug in Europe will pay dividends.
